Skip to main content
A

Aptabio Therapeutics Inc. — Investor Relations & Filings

Ticker · 293780 ISIN · KR7293780003 KO Manufacturing
Open in API
Filings indexed 208 across all filing types
Latest filing 2026-04-14 Regulatory Filings
Country KR South Korea
Listing KO 293780

About Aptabio Therapeutics Inc.

https://aptabio.com/

Aptabio Therapeutics Inc. is a biopharmaceutical company dedicated to developing first-in-class drugs for intractable diseases with high unmet medical needs. The company's research is driven by proprietary platform technologies. One core platform focuses on regulating oxidative stress through selective NOX (NADPH oxidase) inhibitors, targeting the root causes of inflammation and fibrosis to treat diabetic complications, vascular diseases, and neurodegenerative disorders. A second platform centers on the regulation of cancer-associated fibroblasts (CAF) to overcome resistance and enhance the efficacy of immuno-oncology therapies for difficult-to-treat cancers. By leveraging these distinct approaches, Aptabio aims to discover and advance novel therapeutic candidates for challenging medical conditions.

Recent filings

Filing Released Lang Actions
투자판단관련주요경영사항(임상시험계획승인신청등결정) (조영제유발급성신장손상(CIAKI)치료제 Isuzinaxib(APX115)의 미국 FDA 2상 임상시험계획(IND)변경승인)
Regulatory Filings Classification · 1% confidence The document is a Korean ‘투자판단 관련 주요경영사항’ disclosure announcing FDA approval of a clinical trial plan change. It is a routine material event announcement to the exchange, not a full report (e.g., 10-K, IR) nor an earnings release, management change, share action, or similar. Therefore it falls into the general ‘Regulatory Filings’ fallback category (RNS).
2026-04-14 Korean
기업설명회(IR)개최
Investor Presentation Classification · 1% confidence The document is an announcement of a corporate investor relations event (기업설명회/IR) with details on date, time, location, participants, purpose, and where IR materials will be posted. This corresponds to an Investor Presentation announcement rather than a full report or a simple notice of dividend, regulatory filing, etc. Therefore, it should be classified as an Investor Presentation (IP).
2026-04-06 Korean
본점소재지변경
Regulatory Filings Classification · 1% confidence The document is a brief regulatory announcement notifying stakeholders of a change in the company’s head office location, with details of the old and new addresses, reason for change, and effective dates. It does not discuss financial results, dividends, share issues, management changes, or contain full report content; it is a miscellaneous corporate disclosure. It therefore falls under the fallback category Regulatory Filings (RNS).
2026-04-01 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is the official record of resolutions and voting outcomes at the company’s 2026 Annual General Meeting, listing approved financial statements, director appointments, dividend decisions, and vote tallies for each agenda item. This corresponds to “Declaration of Voting Results & Voting Rights Announcements” rather than AGM presentation materials or other filings.
2026-03-31 Korean
기업설명회(IR)개최
Investor Presentation Classification · 1% confidence The document is an announcement detailing the date, time, venue, purpose, and format of an upcoming 기업설명회 (IR) – an Investor Relations presentation/event. This matches the “Investor Presentation” category (IP).
2026-03-27 Korean
기업설명회(IR)개최
Investor Presentation Classification · 1% confidence The document is a Korean-language announcement for an upcoming corporate investor relations meeting (기업설명회/IR) with details on dates, venue, target investors, agenda, and posting of IR materials. This corresponds to an Investor Presentation (IR) event notice rather than a financial report or earnings release. Therefore, it should be classified under Investor Presentation (IP).
2026-03-26 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.